A healthcare professional who was admitted to Rikshospitalet due to a blood clot after receiving AstraZeneca died. It is currently being investigated whether this is related to the vaccine.
Vaccinations suspended
Norway suspended vaccination with AstraZeneca on Thursday. This happened after reports from Denmark and other countries about possible side effects in the form of blood clots.
At a press conference Monday afternoon, Madsen stated that the employee health service, who was admitted to Rikshospitalet after suffering a blood clot, died. It will now be investigated whether the death was linked to the AstraZeneca vaccine.
- On Saturday, the Norwegian Medicines Agency and NIPH announced that three people who had been vaccinated had been admitted to Rikshospitalet due to serious cases of blood clots. Rikshospitalet confirms that one of the patients is dead, says Madsen.
- The Norwegian Medicines Agency emphasizes that this is a rare symptom. They have a very unusual combination of low platelet counts, clots in small and large vessels, and bleeding. Cases with a similar symptom of the disease have been reported in several other European countries, he continues.
The deceased woman was less than 50 years old, was employed at a hospital in Lillehammer and was previously healthy, reports Rikshospitalet.
- Unfortunately, life could not be saved. She died yesterday. It was a healthy person. She received the maximum intensive care we could provide at Rikshospitalet, said head doctor Trine Kåsine of the University Hospital in Oslo.
The woman was vaccinated one week before admission to the local hospital. Later she was taken to Rikshospitalet.
The Norwegian Medicines Agency is investigating whether there is a link between vaccines and cases of blood clots.
- Three serious cases of blood clots, bleeding and a low platelet count following vaccination with AstraZeneca. Such cases have not yet been recorded after vaccination with other vaccines, says Madsen.
This week's calls
To date, more than 120 Norwegians have been vaccinated with AstraZeneca. Madsen says there is little risk of serious side effects if 000 days have passed since the vaccination.
The Norwegian Medicines Agency has received around 1000 new reports of side effects in recent days, but most of them are mild.